CRS Clinical Research Services Berlin GmbH

CRS Clinical Research Services Berlin GmbH is a German company name in the clinical research services sector, indicated by its legal form (GmbH) and its Berlin designation. The name points to a contract research organization (CRO) offering clinical trial execution and related services to pharmaceutical, biotechnology and medical-device sponsors. The supplied evidence does not contain any material about this company: the two snippets are unrelated Chinese-language news articles, one about an OpenAI security incident report and one about shampoo frequency and scalp health. No official website, founding date, founder, ownership structure, executive team, service portfolio, facility details or client information could be verified from the evidence provided. Because the identity of the entity cannot be confirmed beyond the name itself, this entry is deliberately limited. It should be treated as a placeholder pending verification against the company's own website, German commercial register (Handelsregister) filings, or industry directories of clinical research organizations. No products, campaigns, milestones or financial details are asserted here, since doing so would require invention.

No verifiable history of CRS Clinical Research Services Berlin GmbH is available in the supplied evidence. The company name indicates a German limited-liability entity (GmbH) based in Berlin and active in clinical research services, but founding date, ownership changes, facility expansions and leadership history cannot be documented from the material provided. A full history should be compiled from the company's own website, German commercial register records and industry sources before publication.

• 2026-08-27

  hVIVO acquires CRS Clinical Research Services Berlin[3]hVIVO收购CRS柏林临床研究服务公司investegate.co.uk

  hVIVO plc announced the acquisition of the entire issued share capital of CRS Clinical Research Services Berlin GmbH, a specialist Phase I/II clinical research unit focused on dermatology and women's health, for initial consideration of €0.025 million plus a three-year revenue-based earnout expected to total approximately €6 million in cash.

1. 1OpenAI发布Hugging Face安全事件官方报告163.com
2. 2「每天洗头」到底好不好？两项研究：较高的洗发频率对亚洲人群的头皮和头发健康有益，但护发产品的使用需警惕！163.com
3. 3hVIVO收购CRS柏林临床研究服务公司investegate.co.uk
4. 4hVIVO plc: hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health marketsfinanznachrichten.de